Haratani et al. reported subgroups of EGFR-mutated NSCLC patients with PD-L1 expression and high TMB, or that had acquired resistance to EGFR-TKIs by a mechanism other than the development of T790M mutation, possibly achieving a treatment benefit from ICIs [111]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.